In surgical studies of breast and prostate cancer, short-term inhibition of COX-2 has shown an increase in apoptosis in neoplastic cells and a reduction in the proliferation, angiogenesis, and expression of HIF-1α. Here, PTGS2 is linked to prostate carcinoma.